Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10332172 | 0.95 | CTSS (0.59) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL22041768 | 0.91 | CTSS (0.50) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL22041903 | 0.91 | CTSS (0.47) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1974652 | 0.90 | CTSB (0.51) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1189554 | 0.89 | CTSS (0.57) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL25249007 | 0.87 | ALDH1A1 (0.51) | CTSSCTSLCTSBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL29158039 | 0.87 | CTSS (0.56) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL3147192 | 0.87 | CTSS (0.48) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL3931521 | 0.87 | CTSS (0.47) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL14690411 | 0.86 | CTSS (0.53) | CTSSCTSLCTSBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146123-A | Synthesis method of An Luoti nii hydrochloride intermediate | 河北鼎泰制药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-9783498-B2 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline | Advenchen Pharmaceuticals, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763998-B1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
| EP-1715873-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS | LG Life Sciences Ltd. (KR) | 2006-11-02 | — | — | EP | disclosed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | disclosed |
| WO-2005079812-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS | LG LIFE SCIENCES LTD. (KR) | 2005-09-01 | — | — | WO | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
| EP-1358198-A1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG Chem Investment, Ltd. (KR) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057288-A1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD. (KR) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | PNP, TYMP, ENTPD5 | CTSS 3026/4885CTSL 1621/4885CTSB 2753/4885 |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CTSS 3009/4885CTSL 2173/4885CTSB 1940/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CTSS 3009/4885CTSL 2173/4885CTSB 1940/4885 |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | MAP3K15, MAP3K1, MAP3K5 | CTSS 2481/4885CTSL 3205/4885CTSB 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.